Bivalirudin for percutaneous coronary interventions: Development perspective

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. F, 2000, Pages

  Bittl, John A ^a,b  

^a Munroe Regional Med Center   (United States)

^b Ocala Heart Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; DRUG DERIVATIVE; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAFETY; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTITHROMBINS; CORONARY THROMBOSIS; HIRUDINS; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SAFETY; SURVIVAL RATE;

EID: 0034575642     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Fernández-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-1569.
2. Strony J, Beaudoin A, Brands D, Adelman B. Analysis of shear stress and hemodynamic factors in a model of coronary artery stenosis and thrombosis. Am J Physiol 1993;265:H1787-H1796.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathophysiology of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250,310-318.
4. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
5. The EPILOG investigators. Evaluation of PTCA to improve long-term outcome by c7E3 glycoprotein IIb/IIIa receptor blockade (EPILOG). N Engl J Med 1997;336:1689-1696.
6. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
7. Topol EJ, Mark DB, Lincoff AM, et al., for the EPISTENT investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicenter randomized trial. Lancet 1999;352:2019-2024.
8. Tcheng JE, Harrington RA, Kottke-Marchant K, et al., for the IMPACT investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention. Circulation 1995;91:2151-2157.
9. The ESPRIT investigators. The ESPRIT study: A randomized, placebo-controlled trial of a novel dosing regimen of eptifibatide in planned coronary stent implantation. Lancet 2000;354:in press.
10. Grüentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation for coronary artery stenosis - Percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68.
11. Wilcox JN, Smith KN, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci 1989;86:2839-2843.
12. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91:619-622.
13. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996;380:41-46.
14. Marmur JD, Merlinie PA, Sharma SK, et al. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994;24:1484-1491.
15. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
16. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci 1989;86:3619-3623.
17. Eitzmann DT, Chi L, Saggin L, et al. Heparin neutralization by platelet-rich thrombi: Role of platelet factor 4. Circulation 1994;89:1523-1529.
18. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
19. Narins CR, Hillegass WB Jr., Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:660-671.
20. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-643.
21. Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-695.
22. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
23. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for acute coronary syndromes. Circulation 1999;100:2049-2053.
24. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-7101.
25. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
26. Bittl JA, Strony J, Brinker JA, et al., for the Hirulog Angioplasty study investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
27. Wolfe MW, Roubin GS, Schweiger M, et al., on behalf of the Heparin Registry investigators. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty: Clinical and procedural predictors. Circulation 1995;92:311-319.
28. Popma JJ, Coller BS, Ohman EM, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1995;108:486S-501S.
29. Bittl JA, Chaitman BR, Feit F, et al., on behalf of the Bivalirudin Angioplasty investigators. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final report of the Bilvalirudin Angioplasty Study. Am Heart J, (submitted).
30. Bittl JA, on behalf of the Hirulog Angioplasty Study investigators. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. Am Heart J 1995;130:658-665.
31. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
32. Campbell KR, Mahaffey KW, Lewis DE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol 2000;12 (Suppl F):14F-19F.
33. Nicolini FA, Lee P, Rios G, et al. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994;89:1802-1809.
34. Kleiman NS, Lincoff AM, Sapp SK, et al. Pharmacodynamics of a direct thrombin inhibitor combined with a GP IIb/IIIa antagonist: First experience in humans. Circulation 1999:100 (Suppl);I-328.
35. Temple RJ. When are clinical trials of a given agent vs. placebo no longer appropriate or feasible? Controlled Clinical Trials 1997;18:619.